
    
      Group A (Lamivudine Monotherapy): Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd.

      Group B (Oxymatrine + Lamivudine Combination Therapy): Lamivudine (Manufacturer:
      GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group
      Co., Ltd) 200 mg, po, tid.

      Total subjects: 200, 100 patients randomized in each group.
    
  